2020 Wells Fargo Virtual Healthcare Conference Read more about 2020 Wells Fargo Virtual Healthcare Conference
bluebird bio Announces September Investor Events Read more about bluebird bio Announces September Investor Events
bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT Read more about bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT
bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting Read more about bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting
Denice Torres Member of the Compensation CommitteeMember of the Nominating and Corporate Governance Committee Denice Torres Director
bluebird bio Appoints Denice Torres to Board of Directors Read more about bluebird bio Appoints Denice Torres to Board of Directors
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress Read more about bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress
Canaccord Genuity 40th Annual Growth Conference Read more about Canaccord Genuity 40th Annual Growth Conference
bluebird bio Announces August Investor Event Read more about bluebird bio Announces August Investor Event
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma Read more about Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma